NEW YORK--(BUSINESS WIRE)--Artificial Intelligence (AI)-driven Primary Care company K Health announces today the publication of its peer-reviewed research in Mayo Clinic Proceedings: Digital Health, ...
Several new antihypertensive agents are reshaping the therapeutic strategies for patients with uncontrolled or resistant hypertension (RH). Agents such as baxdrostat, the first selective aldosterone ...
Orchestra BioMed’s hypertension treatment is the latest medical device to earn the FDA’s breakthrough designation. The device is an atrio-ventricular interval modulation therapy, meaning it uses a ...
Mineralys Therapeutics announced the results of the Phase 3 Launch-HTN trial, the largest hypertension study involving an aldosterone synthase inhibitor, which included over 1,000 participants with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results